Supriya Lifesci.
Biotechnology · SUPRIYA
Small CapHealthcareHigh Growth
Dr. Saloni Satish Wagh
Managing Director · Transformational
Company DNA
Founder-Centric
About
Supriya Lifesci. is a Small Cap company in the Healthcare sector, listed on NSE as SUPRIYA. With a market cap of ₹5K Cr and revenue of ₹680 Cr, it is currently in the High Growth phase. Known for its Founder-Centric culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. The company maintains a high promoter control with the MD directly involved in steering the R&D and manufacturing trajectory. Its strategic mandate: Scaling API manufacturing footprint globally requires strategic investments in R&D and geographic market penetration.
FAQ
What kind of company is Supriya Lifesci.?
Supriya Lifesci. is a Small Cap Healthcare company (SUPRIYA) in the High Growth phase with a market cap of ₹5K Cr. It is classified as Founder-Centric in culture.
What is Supriya Lifesci.'s culture and work environment like?
Supriya Lifesci. has a Founder-Centric culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Steady Employer. Customer relationship style: B2B-Enterprise. The company maintains a high promoter control with the MD directly involved in steering the R&D and manufacturing trajectory.
Who leads Supriya Lifesci.?
Supriya Lifesci. is led by Dr. Saloni Satish Wagh (Managing Director), a Transformational leader with 16 years of experience.
What are Supriya Lifesci.'s financials?
Supriya Lifesci. reported revenue of ₹680 Cr in FY25 with a 5-year revenue CAGR of 9.4%. Operating margin: 34.7%. Market cap: ₹5K Cr.
Culture & Strategy
CultureFounder-Centric
InnovationFast-Follower
PaceSteady-Marathon
PurposeProfit-Pure
CustomerB2B-Enterprise
EmployeeSteady Employer
BrandTechnical-Expert
LifecycleHigh Growth
The company maintains a high promoter control with the MD directly involved in steering the R&D and manufacturing trajectory.
Mandate
Scaling API manufacturing footprint globally requires strategic investments in R&D and geographic market penetration.
Scaling API manufacturing footprint globally requires strategic investments in R&D and geographic market penetration.
Financials
Revenue FY25₹680 Cr
PAT FY25₹188 Cr
Rev CAGR 5Y9.4%
OPM34.7%
NPM27.7%
ROE18.9%
ROCE22.9%
P/E25.1
Fwd P/E18.8
P/B4.3
D/E0.5
Mkt Cap₹5K Cr
Promoter70.8%
Institutional3.8%
Similar Culture
Could You Lead Supriya Lifesci.?
Take the Genome Benchmark →